Renin Angiotensin System Blockade in Kidney Transplantation: A Systematic Review of the Evidence

https://doi.org/10.1111/j.1600-6143.2007.01928.xGet rights and content
Under a Creative Commons license
open archive

ACE‐inhibitors and angiotensin receptor blockers (ARB) slow the progression of renal disease in nontransplant patients. A systematic review of randomized trials (n = 21 trials with 1549 patients) was conducted to determine the effect of ACE‐inhibitor or ARB use following kidney transplantation. With a median follow‐up of 27 months, ACE‐inhibitor or ARB use was associated with a significant decrease in glomerular filtration rate (−5.8 mL/min; 95% CI −10.6 to −0.99). ACE‐inhibitor or ARB use resulted in a lower hematocrit (−3.5%; 95% CI −6.1 to −0.95), reduction in proteinuria (−0.47 gm/d; 95% CI −0.86 to −0.08) but no change in the serum potassium (0.18 mmol/L; 95% CI −0.03 to 0.40). ACE‐inhibitor or ARB use results in clinically important reductions in proteinuria, hematocrit and glomerular filtration rate in renal transplant recipients, but there are insufficient data to determine the effect on patient or graft survival. Randomized trials of sufficient power and duration that examine these hard outcomes should be conducted. Until such trials are completed, this study provides quantitative estimates of the risks and benefits of ACE‐inhibitor or ARB use that can be used by clinicians considering prescribing these medications to kidney transplant recipients or to researchers designing future trials.

Key words:

ACE‐inhibitor
angiotensin receptor blocker
kidney transplantation
meta‐analysis
randomized trial
systematic review

Cited by (0)